NeoGenomics, Inc.

As of June 30, 2026, NeoGenomics, Inc. carries a market capitalization of 22.75B, placing it among publicly traded companies globally. Its enterprise value stands at 28.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

NeoGenomics, Inc.'s next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, NeoGenomics, Inc. has 127.92M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.71, and the price-to-book ratio stands at 1.66.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 28.04B versus a market cap of 22.75B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, NeoGenomics, Inc. maintains a current ratio of 3.60, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 57.06, indicating elevated leverage, while an interest coverage ratio of -1.16 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, NeoGenomics, Inc. posted a negative return on equity (ROE) of -6.33, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.78, reflecting losses generated across the asset base. The company generates approximately 5.52M in revenue per employee across its workforce of 2,425.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 14.02 indicates how many times NeoGenomics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, NeoGenomics, Inc. recorded an income tax benefit of -46.63M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -953.02M and -906.39M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 1, 2026, NeoGenomics, Inc.'s stock has gained approximately 69.50% over the past 52 weeks.

Over the twelve months ended June 30, 2026, NeoGenomics, Inc. generated 13.39B in revenue and converted that into -906.39M in net income, yielding earnings per share of -7.01. EBITDA reached -52.15M, while operating income came in at -1.06B.

As of June 30, 2026, NeoGenomics, Inc. holds 2.54B in cash and equivalents against 7.83B in total debt, resulting in a net debt position of 4.00B. Total book value stands at 13.73B, with working capital of 4.82B providing operational flexibility.

NeoGenomics, Inc. produced 385.23M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -513.73M in capital expenditures, free cash flow totaled -128.50M - equivalent to -1.00 per share.

Over the twelve months ended June 30, 2026, NeoGenomics, Inc. posted a gross margin of 43.92, reflecting its pricing power and cost economics. The operating margin of -7.92 and net profit margin of -6.77 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.56: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.87, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to NeoGenomics, Inc. shareholders.

NeoGenomics, Inc.'s most recent stock split took place on April 16, 2003 with a 100:1 split ratio.

As of June 30, 2026, NeoGenomics, Inc. has an Altman Z-Score of 1.86, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.